Among 98 assessable samples, 73.5% (n = 72) overexpressed HLA-E (scoring 2 and 3, called HLA-Ehigh) and 26.5% (n = 26) expressed normally or low HLA-E (scoring 0 and 1, called HLA-Elow) on tumor cells. Here, HLA-E is linked to neoplasm.